Innovative molecular cytogenetic techniques for early leukemia/lymphoma detection

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43CA117161-01
Agency Tracking Number: CA117161
Amount: $231,815.00
Phase: Phase I
Program: SBIR
Awards Year: 2005
Solicitation Year: 2005
Solicitation Topic Code: N/A
Solicitation Number: PHS2005-2
Small Business Information
Chromotrax, Inc., 2000 N 14Th St, Ste 530, Arlington, VA, 22201
HUBZone Owned: N
Woman Owned: Y
Socially and Economically Disadvantaged: Y
Principal Investigator
 (703) 558-3400
Business Contact
Phone: (703) 558-3400
Research Institution
DESCRIPTION (provided by applicant): We propose an innovative approach combining two separate, novel techniques to greatly enhance accurate detection of leukemia or lymphoma cells, which can be used ultimately for diagnostics and early detection of minimal residual disease (MRD) in bone marrow, lymph nodes, and peripheral blood. The novel techniques of our approach are: (1) A two-step method to generate repetitive sequences depleted DMA probes. The method includes subtracting hybridized biotin-labeled repetitive-sequence DNA complex with phenol and chloroform and a second subtraction using avidin labeled magnetic beads. The unique sequences are then recovered using our dual unique sequence primers. (2) A novel technique of hybridizing chromosomes in suspension with fluorescently-labeled repetitive sequences depleted DNA probes, in combination with flow cytometric analysis or magnetic sorting, in order to sensitively, precisely and rapidly quantify leukemia or lymphoma-related chromosome translocations and rearrangements. Morphologic examination has a detection sensitivity of 1 in 100. PCR technique is very sensitive, but lack of accurate quantitation still is a problem. By contrast, hybridizing chromosomes in suspension has a potential sensitivity of 1 in 1,000,000. We propose to use leukemia as a model to demonstrate solution hybridization technique in conjunction with repetitive sequences depleted DNA probes as a sensitive and specific technique for accurate detection of MRD. Early detection of MRD will increase patient survival and profoundly impact cancer patient management.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government